Dexolve

Dexolve
Product Description

Dexolve is the first generic USP and EP-conform Betadex Sulfobutyl Ether Sodium for:• solubility enhancement (10 to 100,000 fold) • Improvement of chemical stability • Increased bioavailability, facilitated delivery • Reduced aggregation • Moderate irritationor reduced side-effects • Maximized safety, complete renal elimination • Enables formulation of water-insoluble APIs in all dosage forms • Lower API doses to be achieved • Maintained DMF TypeIV in US, Canada, China • Prepared via a self-developed proprietary, patented technology with a process independent from any existing patents • 48-month stability data • Successful production of over 150 subsequent USP compl. batches •  No down payment, No milestone payment, No royalty payment • Over 60 APIs in development using Dexolve

Read more Show less

CYCLOLAB Ltd.

  • HU
  • 2019
    On CPHI since
  • 4
    Certificates
  • 50 - 99
    Employees
Company types
Drug delivery device Supplier/Manufacturer
Primary activities
Contract Research Organisation
Excipients Manufacturer
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    1824-10-0
  • Supplied from
    Hungary
More specifications Fewer specifications

CYCLOLAB Ltd.

  • HU
  • 2019
    On CPHI since
  • 4
    Certificates
  • 50 - 99
    Employees
Company types
Drug delivery device Supplier/Manufacturer
Primary activities
Contract Research Organisation
Excipients Manufacturer
View company profile

More Products from CYCLOLAB Ltd. (4)

  • Heptakis-2,6-dimethyl-beta-cyclodextrin

    Product Heptakis-2,6-dimethyl-beta-cyclodextrin

    DIMEB
  • SGM

    Product SGM

    Sugammadex is one of the greatest successes in the history of cyclodextrins. There is an increasing interest for this product and for the development of Sugammadex since the approval by the FDA resulted in a 3-4-fold increase in the global sales of the product. SGM is used in anesthesia as an injectable an...
  • Hydroxypropyl beta cyclodextrin

    Product Hydroxypropyl beta cyclodextrin

     HPBCD (EP, USP/NF)
  • Sugammadex

    Product Sugammadex

    Sugammadex is one of the greatest successes in the history of cyclodextrins. There is an increasing interest for this product and for the development of Sugammadex since the approval by the FDA resulted in a 3-4-fold increase in the global sales of the product. SGM is used in anesthesia as an injectable an...

CYCLOLAB Ltd. resources (3)

  • Company introduction – Cyclolab Cyclodextrin Research and Development Ltd

    News Company introduction – Cyclolab Cyclodextrin Research and Development Ltd

    CycloLab Cyclodextrin Research and Development Ltd. is a private SME with the focus on cyclodextrin research and development for over 30 years. We are working in the fields of pharmaceutical, cosmetic and food industry, agrochemical, environmental and analytical applications of cyclodextrins.
    19 Oct 2020
  • Cyclolab Dexolve Presentation

    Brochure Cyclolab Dexolve Presentation

    After a precise development work CycloLab established and validated the production of pharma grade Betadex Sulfobutyl Ether Sodium formulation excipient (SBECD, DexolveTM) in 2008. This cyclodextrin is the main component of several commercial formulations worldwide acting as a solubility and stability enhancer.
    DMF documentations were filed to the FDA (DMF No. 21922)in 2008, to Health Canada (DMF No. 2009-080) in 2009 and to China CDE in 2019 (No.F20190000489), all maintained ever since. In addition, CycloLab is a registered manufacturer of the Betadex Sulfobutyl Ether Sodium in the EudraGMDP database.

    The facility is dedicated to the production of SBECD with multiple tons annual capacity (over 350 kg/batch). Our proprietary technology is extremely robust, no OOS results have been obtained after 150 manufactured batches. The production is carried out according to cGMP (OGYÉI-57792-7/2018) and ISO 9001 and the produ...
  • Remdesivir with Dexolve: fight against COVID-19

    News Remdesivir with Dexolve: fight against COVID-19

    CycloLab, being involved in the fight, manufactures the critical excipient: sulfobutyl-ether-BCD (SBECD, Dexolve™) that enables Remdesivir to work. The unexpected and sudden outbreak along with the quick spread of the coronavirus-disease and rapid increase of the cases draw a sudden need for Dexolve.
    22 Sep 2020